Why subscribe?

ADCOM is the flagship program of LDMG and is geared towards drug development sickos who want to understand the nitty gritty details of assets in development.

But we do more than that, our show provides exclusive information on pharmaceutical assets currently in development that includes valuations, chances of success and investment efficiency and is powered by our valuation product The Console.

Once you subscribe you will be notified of when ADCOM episodes goes live.

Subscribe to get full access to the newsletter and publication archives.

Stay up-to-date

Hate for you to miss exclusive information so get the Substack app to get notified when a new show and newsletter drops.

Keep in touch

We would love to hear from you to let us know what you think of our valuations. Email is [email protected]

To learn more about the tech platform that powers this publication, visit Substack.com.